NVIC Articles

Disease-Vaccine-Landing-Page

Disease-Vaccine-Landing-Page

Latest articles

Browse Articles

Placeholder image
Page

A live-virus nasal flu vaccine, FluMist, was licensed by the FDA in June 2003 and initially approved use in healthy people between the ages of five and 49.  It was...

Placeholder image
Page

In 2015, the FDA approved Fluad, the first adjuvanted trivalent flu vaccine containing a squalene oil adjuvant (MF59).  This vaccine was approved for fast track licensure by the FDA, despite...

Placeholder image
Page

Cell-Based flu vaccines differ from standard egg-based flu vaccines because animal cells are used to grow the influenza virus.  Currently only one cell-based flu vaccine, Flucelvax, is available in the...

Placeholder image
Page

The recombinant flu vaccine, approved for use in 2013, is manufactured through genetic engineering.  It is produced using insect (armyworm) cells. Flublok is the only recombinant flu vaccine currently licensed...

Placeholder image
Page

The high-dose influenza vaccine, Fluzone, is approved for adults age 65 and older and contains four times the amount of antigen than the standard flu vaccine.  This vaccine was given...

Placeholder image
Page

The most common flu vaccine is the inactivated (killed) influenza vaccine, which is prepared from the fluids of chick embryos inoculated with a specific type(s) of influenza virus.   The...

Placeholder image
Page

In pre-licensing clinical trials, the most frequently reported side effect was injection site pain. Within seven days of receipt of MRESVIA, the most commonly reported systemic adverse events included fatigue,...

Placeholder image
Page

On July 17, 2023, the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV in infants and children up to 24 months...

Placeholder image
Page

According to Moderna, at 3.7 months following administration, MRESVIA RSV vaccine efficacy was reported to be 78.7 percent against RSV illness with two or more symptoms of lower respiratory tract...

Placeholder image
Page

According to GSK, AREXVY RSV vaccine efficacy was reported to be 82.6 percent against the first occurrence of RSV related lower respiratory tract infection in persons 60 through 79 years...

Topics
Select disease / vaccine